Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer
Non-small Cell Lung Cancer - Malignant Pleural Effusion
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms - Pericardial Effusion - Pleural Effusion - Pleural Effusion, Malignant
Conditions: Keywords
non-small cell lung cancer, malignant pleural effusion, bevacizumab, intrapleural injection, pericardial effusion
Study Type
Study Phase
Phase 2
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Bevacizumab
Type: Drug
Overall Status
Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs injection is important in the treatment. Non- cytotoxic drugs include those with a sclerosing effect that produces pleurodesis, which is easy to cause severe chest pain despite of no influence on the following chemotherapy. Tumor angiogenesis is important in producing MPE. Bevacizumab has been administrated locally in treating optic nerve sickness successfully by anti-VEGF mechanism. So we hypothesize that intrapleural bevacizumab is also effective in treating MPE.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Histological or cytological diagnosis of non-small cell lung cancer.

2. Cytological diagnosis of malignant pleural or pericardial effusion (MPE)

3. Symptomatic MPE evaluated by researchers

4. Unsuitable for or reject systemic therapy of tumor

5. Estimated survival of more than 3 months. 6.18 years or older

Exclusion Criteria:

1. Current or recent (within 10 days prior to treatment) use the full amount of inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows prophylactic anticoagulants

2. Be allergic to bevacizumab

3. Pregnant or lactating woman

4. Pleural or pericardial infection
The First Affliliated Hospital of Guangzhou MC
Guangzhou, Guangdong, China
Status: Recruiting
Contact: Haihong Yang, MD - 00862083062821
Start Date
January 2014
Completion Date
June 2016
Haihong Yang, MD, Pricipal investigator
Guangzhou Medical University
Record processing date processed this data on July 28, 2015 page